We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B Turnover 10.26%
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+49.01%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$1.43B
AUM Growth
-$263M
Cap. Flow
-$141M
Cap. Flow %
-9.8%
Top 10 Hldgs %
54.7%
Holding
66
New
3
Increased
9
Reduced
40
Closed
4
Avg Time Held
3.4 years
Top 10 Avg Time Held
1.7 years
Top 20 Avg Time Held
1.5 years

Top Buys

Rank Stock Value
1
NGNE icon
Neurogene
NGNE
+$13.2M
2
CBLL icon
CeriBell Inc
CBLL
+$11.9M
3
RAPT icon
RAPT Therapeutics
RAPT
+$9.48M
4
LIVN icon
LivaNova
LIVN
+$8.64M
5
SLN icon
Silence Therapeutics
SLN
+$6.45M

Top Sells

Rank Stock Value
1
AUGX icon
Augmedix, Inc. Common Stock
AUGX
+$38.5M
2
CTLT icon
CATALENT, INC.
CTLT
+$36.1M
3
SRRK icon
Scholar Rock
SRRK
+$22.4M
4
KYMR icon
Kymera Therapeutics
KYMR
+$13.2M
5
FOLD icon
Amicus Therapeutics
FOLD
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
IDYA icon
26
IDEAYA Biosciences
IDYA
$3.27B
$15.9M 1.11%
619,300
-61,850
-9% -$1.75M
2023 Q4
4 quarters
CLDX icon
27
Celldex Therapeutics
CLDX
$2.27B
$15.6M 1.08%
615,775
-41,400
-6% -$1.12M
2020 Q2
18 quarters
ESTA icon
28
Establishment Labs
ESTA
$1.83B
$14.7M 1.03%
320,149
+58,346
+22% +$2.54M
2024 Q1
3 quarters
IMVT icon
29
Immunovant
IMVT
$5.68B
$14.2M 0.99%
571,824
-70,405
-11% -$2M
2022 Q4
8 quarters
CBLL icon
30
CeriBell Inc
CBLL
$1.06B
$11.3M 0.79%
+435,239
New +$11.9M
2024 Q4
0 quarters
SYK icon
31
Stryker
SYK
$112B
$11M 0.77%
30,676
-2,065
-6% -$765K
2022 Q3
9 quarters
RAPT icon
32
DELISTED
RAPT Therapeutics
RAPT
$10.2M 0.71%
809,415
+746,348
+1,183% +$9.48M
2022 Q1
11 quarters
BNTX icon
33
BioNTech
BNTX
$22.7B
$9.51M 0.66%
83,471
-70,985
-46% -$8.1M
2024 Q3
1 quarter
ISRG icon
34
Intuitive Surgical
ISRG
$151B
$8.84M 0.62%
16,943
-9,755
-37% -$5.08M
2023 Q4
4 quarters
KROS icon
35
Keros Therapeutics
KROS
$220M
$8.75M 0.61%
552,506
– –
2024 Q1
3 quarters
NUVB icon
36
Nuvation Bio
NUVB
$1.67B
$8.06M 0.56%
3,031,009
– –
2021 Q1
15 quarters
ARDX icon
37
Ardelyx
ARDX
$844M
$7.99M 0.56%
1,576,259
-84,504
-5% -$467K
2024 Q1
3 quarters
ORKA icon
38
Oruka Therapeutics
ORKA
$4.89B
$7.98M 0.56%
411,728
– –
2024 Q3
1 quarter
VERV icon
39
DELISTED
Verve Therapeutics
VERV
$7.43M 0.52%
1,318,164
-65,202
-5% -$368K
2021 Q2
14 quarters
STTK icon
40
Shattuck Labs
STTK
$555M
$6.7M 0.47%
5,539,724
-75,765
-1% -$93.9K
2020 Q4
16 quarters
FDMT icon
41
4D Molecular Therapeutics
FDMT
$711M
$6.67M 0.46%
1,196,910
-65,180
-5% -$512K
2024 Q1
3 quarters
ALXO icon
42
ALX Oncology
ALXO
$138M
$6.16M 0.43%
3,689,611
-146,965
-4% -$226K
2020 Q3
17 quarters
PEN icon
43
Penumbra
PEN
$12.7B
$6.11M 0.43%
25,743
+11,896
+86% +$2.7M
2024 Q3
1 quarter
PRME icon
44
Prime Medicine
PRME
$655M
$6.06M 0.42%
2,074,350
– –
2022 Q4
8 quarters
ATRA icon
45
Atara Biotherapeutics
ATRA
$96.9M
$5.88M 0.41%
441,701
-10,569
-2% -$111K
2014 Q4
40 quarters
CYTK icon
46
Cytokinetics
CYTK
$8.89B
$4.36M 0.3%
92,598
-4,518
-5% -$235K
2024 Q1
3 quarters
STXS icon
47
Stereotaxis
STXS
$105M
$4.1M 0.29%
1,799,465
-308,754
-15% -$646K
2019 Q3
21 quarters
ALLK icon
48
DELISTED
Allakos
ALLK
$3.65M 0.25%
3,015,097
-62,731
-2% -$65.9K
2018 Q3
25 quarters
ATXS icon
49
DELISTED
Astria Therapeutics
ATXS
$3.1M 0.22%
346,278
+35,394
+11% +$376K
2024 Q3
1 quarter
ACIU icon
50
AC Immune
ACIU
$244M
$2.79M 0.19%
1,034,299
-659,868
-39% -$2.06M
2023 Q4
4 quarters
1
2
3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q4 2024 Portfolio in Review

As of Q4 2024, Redmile Group held 66 positions worth $1.43B, down 15% from $1.7B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Redmile Group withdrew a net $141M in Q4 2024, closing 4 positions and reducing 40 holdings. Its most notable exit was Augmedix, Inc. Common Stock, an estimated $38.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Industrials.

Against the trend, Redmile Group opened a new position in CeriBell Inc worth $11.3M.

  • Redmile Group's largest Q4 2024 buy was CeriBell Inc: 435,239 shares worth $11.3M.
  • Redmile Group added most to Neurogene in Q4 2024, an estimated $13.2M increase.
  • Redmile Group's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $22.4M.
  • Redmile Group fully exited Augmedix, Inc. Common Stock in Q4 2024, selling an estimated $38.5M.
  • Redmile Group's ten largest holdings make up 55% of its $1.43B portfolio in Q4 2024.
  • Redmile Group opened 3 new positions and closed 4 in Q4 2024.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $1.43B.

Based on Redmile Group's 13F filing for Q4 2024, filed 14 Feb 2025.